Cytosine-5 DNA methylation is a critical signal de®ning heritable epigenetic states of transcription. As aberrant methylation patterns often accompany disease states, the ability to target cytosine methylation to preselected regions could prove valuable in re-establishing proper gene regulation. We employ the strategy of targeted gene methylation in yeast, which has a naturally unmethylated genome, selectively directing de novo DNA methylation via the fusion of C5 DNA methyltransferases to heterologous DNA-binding proteins. The zinc-®nger proteins Zif268 and Zip53 can target DNA methylation by M.CviPI or M.SssI 5±52 nt from single zinc-factor binding sites. Modi®cation at speci®c GC (M.CviPI) or CG (M.SssI) sites is enhanced as much as 20-fold compared with strains expressing either the free enzyme or a fusion protein with the zinc-®nger protein moiety unable to bind to DNA. Interestingly, methylation is also selectively targeted as far as 353 nt from the zinc-®nger protein binding sites, possibly indicative of looping, nucleosomes or higher-order chromatin structure. These data demonstrate that methylation can be targeted in vivo to a potentially broad range of sequences using speci®cally engineered zinc-®nger proteins. Furthermore, the selective targeting of methylation by zinc®nger proteins demonstrates that binding of distinct classes of factors can be monitored in living cells.
INTRODUCTION
Methylation of the C5 atom of cytosine in DNA (m 5 C) plays an important role in establishing correct patterns of gene expression in vertebrates, usually through repression of transcription. Mechanistically, one way DNA methylation can lead to transcriptional silencing is by decreasing the binding af®nity of a transcriptional activator for its site (1) . The introduction of m 5 C at sites adjacent to a factor binding site can also interfere with its binding (2) . Perhaps more importantly, symmetrical methylation of CpG sequences (CG) serves as a signal for the recruitment of a family of methylCpG binding domain (MBD) proteins, such as MeCP2 and MBD2 (3) . In turn, MBDs, either by themselves or as components of complexes, are known to recruit a variety of co-repressors, such as histone deacetylases (4±7), histone H3 lysine-9 methyltransferases (8) and heterochromatin coating factors like HP1 (9) , which can function to establish a local, repressed region of chromatin (10±15). This silencing mechanism is also conserved in plants, as the DNA chromomethyltransferase CMT3, which methylates CNG residues, interacts with HP1 to facilitate heterochromatin formation (8) .
While regions of m 5 C are often associated with hypoacetylation of histones H3 and/or H4 and altered chromatin structure (10±15), recent evidence suggests DNA methylationand histone deacetylase-independent modes of silencing. First, trichostatin A, a speci®c inhibitor of histone deacetylation, fails to reactivate transcription from densely methylated DNA (2,11,12,15±17) . Additionally, mbd2-null mice are viable and fertile (18) and Mecp2-null mice only display neurological abnormalities (19) , questioning their global role in m 5 Cmediated silencing and cellular differentiation. Moreover, puri®ed MeCP2 itself compacts reconstituted chromatin in the absence of DNA methylation (20) .
Although the mechanisms are not yet fully understood, there is a strong correlation between promoter methylation and gene silencing (1,21±23) . Moreover, once a methylation state is established, it is maintained heritably after many generations of replication (24) by the maintenance DNA methyltransferase (DMTase), Dnmt1 (25) . An exception includes enhancer sequences that can be passively demethylated on replication and subsequent blockage of DMTase access by factor binding (26±30). However, this enhancer-speci®c loss of DNA methylation does not lead to derepression (26) .
Proper regulation of gene expression is essential for normal cellular functions and the avoidance of disease states. DNA methylation, which occurs almost exclusively at CG dinucleotides in non-diseased cells, is localized to precise regions of the genome, usually in transposons and retroviral elements (25) . In contrast, CG sites in euchromatic regions, most notably when concentrated in CpG islands, are generally unmethylated and are correlated with transcriptional activity. However, in cancer and other diseases, patterns of DNA methylation are frequently aberrant. For instance, the DNA in tumor cells is generally hypomethylated relative to that in normal cells (31) , which may lead to genomic instability (23) . In contrast, a number of tumor-suppressor genes, including BRCA1 and retinoblastoma (Rb), become hypermethylated and transcriptionally inactive (32) . The presence of a single methylated CG site in a gene's promoter is suf®cient to repress its activation (21), although higher m 5 C density increases the probability of establishing gene repression (14,33±36) . Thus, DNA methylation can be critical in de®ning the expression state of a gene.
Therefore, directing DNA methylation to improperly regulated loci could be used to re-establish proper gene expression through silencing. Previously, targeting of m 5 C has been demonstrated in vitro (37, 38) , however, selective enrichment of m 5 C was not observed in vivo (38) . Recently, in yeast, using the dinucleotide-speci®city DMTase M.CviPI (39) fused to the basic helix±loop±helix activator Pho4, we demonstrated speci®c targeting of cytosine methylation to promoters containing Pho4 binding sites [targeted gene methylation (TAGM)] (40). Methylation was ef®ciently targeted to GC sites in nucleosomes that were disrupted on promoter activation, as well as to histone-free regions.
In its present form, the TAGM strategy is limited to known factors that bind to well characterized DNA-binding sites, which are often present in multiple copies throughout the genome. Therefore, we have investigated the ability of zinc®nger proteins, which, in principle, may be selected to recognize one or a small subset of chromosomal regions (41) , to target m 5 C in living cells. Whereas preferential targeting of 4 bp speci®city MTases was not observed in vivo (38) , we now show that, in yeast, both M.CviPI (GC methylation) and M.SssI (CG methylation) can be preferentially targeted by zinc-®nger proteins to speci®c GC or CG sites neighboring their cognate binding sites. The potential to direct m 5 C at~20-fold increased resolution to a broad range of desired DNA sequences could lead to novel therapeutic approaches.
MATERIALS AND METHODS

Plasmids, yeast strains and growth conditions
All yeast strains used in this study were derived from the S288C background strain YPH500DL (MATa ade2-101 ura3-52 his3-D200 leu2-D1 trp1-D63 lys2-D1) (26) . Zinc-®nger coding sequences were PCR ampli®ed using the primers MKO46, 5¢-gcactagttaggccagctgggccATGGCTGATATCGG-ATCTGG-3¢, and MKO47, 5¢-gaataattcgAGCGCTTTCAA-GGTCATGGTGGATCCTAGGCCACCTCCACTCC-3¢, and cloned between S®I and AfeI restriction sites as in-frame fusions to either M.CviPI or M.SssI in pMPK1. The fusion proteins are expressed under the control of the GAL1 promoter after integration at LYS2 as previously described (26) . Each N-terminal zinc-®nger protein is separated from the DMTase by a G(SGGGG) 2 SGGGLGST (GS linker) peptide (37) . As a free DMTase control, mutated Zif268 (mut Zif), which contains a single amino acid substitution (H58E) (42) that ablates DNA binding, was constructed by overlap site-directed mutagenesis using the primers MKO72, 5¢-cagtcgtagtgacgAgcttaccacccac-3¢, and MKO73, 5¢-gtgggtggtaagcTcgtcactacgactg-3¢ (mutated residues in upper case).
Cells were pre-grown in yeast extract (Difco)/peptone (Difco)/2% dextrose (YPD) medium and then washed and resuspended at an OD 600 of 0.5 in YP/2% galactose (YPG). After resuspension in YPG, cells were incubated at 30°C for 16 h, or for the indicated times (Fig. 1C) .
Bisul®te genomic sequencing
Total genomic DNA was rapidly isolated by the phenol/ chloroform lysis method (43) and analyzed by bisul®te genomic sequencing (44, 45) as previously modi®ed (26) . PCR ampli®cation from bisul®te-treated genomic DNA with the indicated primer pairs was performed with Jumpstart Taq DNA polymerase (Sigma) and the resulting products were subjected to primer extension using a 32 P-labeled oligonucleotide as described previously using ®nal concentrations of 5 mM dATP, dCTP and dTTP (dGTP omitted) as well as 50 mM ddGTP (26) (Figs 1 and 2 ), or with dNTPs (A, C, T) and ddGTP increased to 50 and 150 mM, respectively (Figs 3±5), as recently reported (40) . Product intensities were determined by ImageQuaNT software (Molecular Dynamics) after subtracting the local background average. Absolute frequencies of cytosine methylation were obtained by dividing the intensity of a given band by all summed product intensities in a given lane, including the run-off product at the top of the gel generated by primer extension on templates lacking cytosine residues (i.e. templates not methylated in vivo). Oligonucleotides used for PCR ampli®cation of bisul®te-treated DNA are described in Table 1 using the original naming conventions of Frommer et al. (44) .
RESULTS
In vivo targeting of C5 DMTases near single, Zif268 binding sites m 5 C has been selectively targeted in vitro by fusing C5 DMTases (M.HhaI, M.HpaII and M.SssI) to zinc-®nger DNAbinding factors (37, 38) . However, attempts to use zinc-®nger proteins as targeting entities in vivo have been unsuccessful (38) . As a ®rst step toward targeting DNA methylation in vivo using zinc-®nger proteins, we tested whether we could increase cytosine methylation levels neighboring zinc-®nger protein binding sites (ZBS) in the genetically tractable eukaryote, Saccharomyces cerevisiae. Yeast genomic DNA does not contain detectable levels of endogenous methylated residues (46) (Figs 4A, lane 4 and 5A and C, lane 5), enabling unambiguous detection of de novo DNA methylation. Also, low-level expression of C5 DMTases in yeast has no known effects on gene expression or growth (26, 27, 47) .
Since chromatin blocks access of DMTases to their target sites (26,27,47±49), our efforts to target m 5 C in vivo focus on the use of enzymes that methylate dinucleotide sites. This substantially increases the probability (~20-fold) that DMTase target sites located in accessible, histone-free regions will be modi®ed. Either of two C5 DMTases, M.CviPI (GC speci®-city) (39) or M.SssI (CG speci®city) (50) , was tethered to the archetypal zinc-®nger protein, Zif268 (51) and expressed as a single-copy, integrated gene under the control of the galactose-inducible GAL1 promoter. The DNA-binding factor that is fused to the DMTase is designated the targeting factor. As a control, we expressed either the untethered DMTase or a fusion protein in which the DNA-binding activity of Zif268 was severely impaired (42) . Strains expressing these`free' DMTase controls establish the level of non-targeted methylation due to enzyme site preferences and accessibility in protein-free DNA and chromatin (26,27,47±49).
Endogenous yeast Zif268 binding sites (5¢-GCGTGGGCG-3¢) were identi®ed by the PatMatch search engine (http:// www.yeastgenome.org/). We determined the relative methylation frequencies at multiple GC (M.CviPI) and CG (M.SssI) sites at the CAR1 locus containing a single, consensus binding site for Zif268 by bisul®te genomic sequencing (see Materials and Methods) (40) . Speci®c binding by the Zif268 moiety of each fusion protein is supported by protection of multiple CG and GC sites against methylation at the Zif268 site in strains expressing a wild-type Zif268 fusion as compared with its respective free DMTase (Fig. 1A±C , compare lanes 1 with 2 and 3 with 4, ®lled bar). Ratios of m 5 C among several sites in a given lane are similar, identifying sites at which non-targeted methylation occurs (®lled circles), which enables normalization for differences in methylation activity between strains. By this criterion, the mut Zif±M.CviPI strain has~2-fold more methylation activity than cells expressing Zif±M.CviPI. The reason for this activity difference is unclear. DNA methylation increased substantially at several sites (asterisks) in cells expressing Zif±M.CviPI and Zif±M.SssI versus mut Zif± M.CviPI and M.SssI, respectively. Targeted modi®cation sites (asterisks) are readily identi®able by normalizing to sites of non-targeted methylation (®lled circles). In the case of Zif± M.CviPI, which targets m 5 C more ef®ciently, 41, 12.4, 2.3 and 2.6% of GC sites 19, 41, 163 and 172, were methylated, respectively. Since the methylation level at each of these sites exceeds that at the normalization site 46 over a time course of Zif±M.CviPI induction, different levels/duration of Zif± M.CviPI expression do not affect the relative ef®ciency of targeting m 5 C (Fig. 1C) . The fold increases in m 5 C at each targeted site in strains expressing Zif±M.CviPI versus mut Zif±M.CviPI in three independent experiments are presented in Figure 1D .
M.CviPI is targeted most ef®ciently to a site located 19 bp from the ZBS (Fig. 1D) , which correlates well with the optimal distance of 10±40 bp observed when methylating oligonucleotides with other DMTase fusion proteins in vitro (37, 38) and in yeast (40) . This optimal distance for introducing m 5 C is likely related to the length and amino acid sequence of the¯exible peptide separating Zif268 and the DMTase (38) . However, targeting methylation distal to the consensus ZBS (e.g. sites 163 and 183) is as or more ef®cient than to some proximal sites (e.g. sites 41, 43 and 52) (Fig. 1A±  D) . Preferential targeting of M.CviPI and M.SssI also occurs distally, at sites 163±183 nt from the ZBS (Fig. 1A±D) . A single, DNA-bound monomer of Zif268 similarly targets both DMTases close to (5±30 bp) and at a considerable distance from (353 bp) a second consensus Zif268 site in YBR108W (+2067 to +2075; Fig. 2A and B) . For a third Zif268 binding site (±397 to ±389 of YOL019W), two GC sites are protected against methylation by Zif±M.CviPI bound at the ZBS, and m 5 C is targeted to an additional GC site 39 bp from the ZBS (Fig. 2C) . In contrast, the relative levels of CG or GC site methylation at the PHO5 promoter, which lacks Zif268 sites, show no signi®cant differences between the wild-type Zif268 fusion and its respective free DMTase control (Fig. 3 , compare lanes 1 with 2 and 3 with 4). We conclude that the targeted methylation is due to site-speci®c DNA binding by Zif268.
Targeting M.CviPI via phage display-selected Zip53
The engineered zinc-®nger protein Zip53, which speci®cally binds to a p53 consensus site (5¢-GGGACATGT-3¢; hereafter Zip53 binding site) (41) , was previously fused to M.SssI and used in vitro to target methylation next to its cognate binding site in an oligonucleotide substrate (37) . We tested if Zip53 could direct methylation by M.CviPI to regions containing a single Zip53 site in vivo. As above, the Zip53±M.CviPI fusion protein was integrated as a single copy at LYS2 and expressed from the GAL1 promoter. First, we analyzed m 5 C levels near the consensus Zip53 binding site located in the DED1 coding 2) and CG (lanes 3 and 4) sites (®lled circles). Note that, relative to the mut Zif±M.CviPI control (lane 1), the lower methylation frequencies in the Zif±M.CviPI strain (lane 2) at each GC site is consistent with the conclusion that it has reduced overall methylation activity. However, the similar ratios of site intensities within lanes 1 and 2 (M.CviPI) as well as within lanes 3 and 4 (M.SssI) demonstrate that m 5 C accumulates independent of the Zif (or mut Zif) fusion moiety. 
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sequence (+284 to +276; Fig. 4 ). As expected, since yeast do not have endogenous cytosine DMTases, no modi®ed cytosines are evident in a strain that does not contain a functional copy of M.CviPI (Fig. 4A, lane 4) . Normalizing to site 141, relative to the`free' DMTase control (mut Zif± M.CviPI), targeted methylation is detected 30 bp from the DED1 consensus Zip53 site on expression of Zip53±M.CviPI (Fig. 4A, compare lanes 2 and 3 with lane 1) . Further, longrange methylation at sites 162 and 178 bp from the consensus ZBS is substantially enhanced. Lastly, there is reproducible, low-level protection of a GC site located 3 bp from the ZBS, indicative of Zip53 binding (Fig. 4A and B) .
We also observed long-range targeting of m 5 C from a second consensus Zip53 site located in the YLR016C coding sequence (+298 to +306; Fig. 5A and B) . Methylation was enhanced 5.5-fold at site 184, and somewhat less, but signi®cantly (~2.2-fold), at sites 157 and 190 in strains expressing Zip53±M.CviPI relative to mut Zif±M.CviPI. Protection against DNA methylation could not be observed because no GC sites are adjacent to or within the Zip53 binding site. To examine the speci®city of the Zip53±DMTase fusion protein, we analyzed m 5 C levels at the CAR1 locus ( Fig. 1) , which contains a Zif268 site, but no Zip53 site (Fig. 5C ). In each lane of the gel in Figure 5C , little to no change exists in the relative methylation levels of 13 GC sites at CAR1. In particular, methylation at site 19 of the CAR1 region, which shows >20-fold enrichment following expression of Zif±M.CviPI (Fig. 1) , is not increased in the presence of Zip53±M.CviPI. This result demonstrates that Zip53 speci®cally binds its site, but not that of Zif268 (the two binding sites have 22% identity). We conclude that, as for Zif268, Zip53 is able to target M.CviPI and thereby signi®-cantly increase cytosine methylation at select GC sites near and distal to a cognate ZBS. The use of Zip53 to deliver m 5 C selectively further demonstrates that zinc-®nger proteins engineered to recognize pre-determined sequences can be used to introduce de novo methylation essentially to any region of interest.
DISCUSSION
In this report, we demonstrate the ability to target m 5 C in vivo using two zinc-®nger proteins, Zif268 and its arti®cially engineered derivative Zip53. First, signi®cant targeting of m 5 C is observed at select sites both adjacent (5±52 bp) and distal (>150 bp) to a cognate, consensus ZBS (Figs 1, 2, 4 and 5A and B), whereas DNA methylation is not enriched at control loci lacking the ZBS (Figs 3 and 5C ). Proximal and distal targeting of m 5 C was also observed in our previous studies using Pho4 as the DMTase targeting factor (40) . The reasons for selective targeting of m 5 C to some sites as opposed to others in the same region are not currently understood. At least locally, the length of the peptide linker separating the DMTase and the targeting factor, the helical face of a particular CG or GC site relative to the DNA-bound targeting factor, and accessibility in chromatin each presumably contribute to the preferential targeting. Secondly, since DNA-bound factors impair access of DMTases to their target sites (26±30,40), the protection against methylation of CG or GC sites next to or within the ZBS provides further evidence of speci®c ZBS binding by each zinc-®nger±DMTase fusion protein. Taken together, in addition to demonstrating selective enrichment of m 5 C near ZBS, TAGM provides a highly sensitive means for detecting protein±DNA interactions (40) .
The occurrence of targeted m 5 C beyond distances of 40 nt suggests that two sites well separated in protein-free DNA are juxtaposed by looping, nucleosomes or higher-order chromatin structure (e.g. Fig. 2A, 353 bp away from the ZBS). While it is formally possible that the occurrence of distal methylation is due to binding at a secondary, non-consensus ZBS, we do not believe this to be the case. First, no footprints are observed near MTase target sites that are >150 bp from the primary Zif268 binding site, despite the fact that high-af®nity sites contain two GC sites. Secondly, within 50 bp of each longrange targeted m 5 C site any potential ZBS has a minimum of four to ®ve mismatches from consensus. Since two or more base substitutions result in background levels of binding (42,52±54) , it is highly unlikely that any of these sites constitute a signi®cant secondary ZBS. Thirdly, it is improbable that distal secondary ZFP binding sites would be present at all ®ve loci that were analyzed. Finally, Dam MTase can also be targeted at a distance (55, 56) .
The design of multiple zinc-®nger modules with desired speci®cities is proving a versatile platform for targeting a variety of protein moieties to accessible sites in vivo (57). For instance, engineered zinc-®nger proteins have been fused to the catalytic domain of R.FokI endonuclease to direct sitespeci®c double-stranded DNA cleavage, and hence homologous recombination, of desired regions (58) . Designed zinc-®nger proteins have also been used to target the catalytic domains of the histone methyltransferases G9A and SUV39H1 (59) as well as the VP16 activation domain (60±62), leading to repression and activation, respectively, of expression of the endogenous human erythropoietin (EPO), vascular endothelial growth factor A (VEGF-A) and other mammalian genes (57) . This technology has also recently been extended to the regulation of gene expression in plants (63) .
The targeting of DMTases by zinc-®nger proteins selected to bind speci®c ZBS could provide an additional way to downregulate the expression of desired genes. Moreover, since the DNA methylation state of a given promoter is maintained heritably through DNA replication by endogenous cellular mechanisms, an initial targeting event may be suf®cient to establish stable silencing of improperly expressed genes. Therefore, heritable repression could also reduce the amount of treatment necessary to establish the proper regulation of a particular gene. In addition to providing a potentially powerful therapeutic tool, methylation-mediated repression of speci®c-ally targeted genes could yield an alternative to transgenic knockouts for studying loss-of-function phenotypes. Silencing genes through DNA methylation would be particularly valuable in the case of essential genes where tissue-speci®c knockouts of function are needed. Optimization of targeting factor occupancy at regions of interest will likely increase the ef®cacy of speci®c m 5 C targeting in vivo as well as minimize non-targeted methylation. The experimental system used herein provides a useful assay for pursuing such further investigations. Finally, the ability to target m 5 C speci®cally in vivo is likely to prove valuable in basic investigations of the biological roles and mechanistic consequences of DNA methylation. GAAAAtAGGGAttAGAATtATAAATTTAGTtT 3 DED1a1±166
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